51.55
+9.82%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Scholar Rock Holding
From its filings with the US Securities and Exchange Commission
Scholar Rock Holding is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SRRK. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $377.9m. At that date it held total assets of $404.3m and shareholders' equity of $245.5m.
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta (“TGFβ”) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Based on our innovative, proprietary, and scalable technology platform, we are building a world-leading anti-myostatin pipeline. During 2025, we made significant progress in advancing our product candidates. We believe 2026 could be a transformational year for Scholar Rock as we anticipate the potential to become a commercial-stage biotech company.
Our lead pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439.
Apitegromab is a novel, investigational, fully human monoclonal antibody that inhibits myostatin activation by selectively binding the pro- and latent forms of myostatin in skeletal muscle. Myostatin is a catabolic agent that functions as a negative regulator of muscle mass, therefore inhibition of myostatin results in increased muscle mass and strength. Apitegromab is in development for the treatment of people with SMA and for the treatment of people with facioscapulohumeral muscular dystrophy (“FSHD”).
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 May 2018
- Employees
- 289
- Website
- scholarrock.com ↗
- Head office
- 301 BINNEY STREET, CAMBRIDGE, MA, 02142
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Mr. David HallalChairman of the Board, Chief Executive Officer, since 2017$400,849
- Mr. Vikas SinhaChief Financial Officer
- Dr. Akshay VaishnawPresident - Research & Development, Director, since 2019$281,257
- Mr. R. Keith WoodsChief Operating Officer
- Ms. Caryn ParlavecchioChief Human Resources Officer
- Ms. Lisa WymanChief Technical and Quality Officer
- Dr. Mo QatananiChief Scientific Officer$3.0m
- Ms. Junlin HoGeneral Counsel, Corporate Secretary$2.1m
- Dr. Adm. Jing MarantzChief Medical Officer$3.1m
- Ms. Tracey SaccoChief Commercial Officer$2.3m
- Ms. Beth ShaferChief Business Officer
- Dr. Srinivas AkkarajuIndependent Director$276,257
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 40
- Environment
- 40
- Social
- 62
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Scholar Rock Holding Corp has a strong research and development team comprising experienced scientists and industry experts. This expertise allows the company to develop innovative and potentially groundbreaking therapies.
- The company has developed a robust pipeline with a focus on targeting TGFβ and myostatin, which are implicated in various diseases. This unique approach positions Scholar Rock as a leader in the development of novel therapeutics.
Weaknesses
- Scholar Rock Holding Corp is a relatively small company compared to some of its competitors in the biopharmaceutical industry. Limited financial resources and a smaller workforce may restrict the company's ability to scale up operations and effectively compete.
- As a clinical-stage biotech firm, Scholar Rock faces significant risks associated with the development and regulatory approval of its drug candidates. Delays in clinical trials or failure to meet regulatory requirements could impact the company's success.
Opportunities
- The biopharmaceutical industry is experiencing substantial growth, driven by increasing demand for innovative therapies to address unmet medical needs. Scholar Rock can leverage this opportunity by advancing its pipeline, securing partnerships, and exploring collaborations with other industry players.
- The company operates in a field with significant potential for breakthrough treatments, particularly in areas such as cancer, fibrosis, and neuromuscular disorders. By successfully developing and commercializing its drug candidates, Scholar Rock can tap into a large and lucrative market.
Threats
- The biopharmaceutical industry is highly competitive, with numerous players vying for market share. Scholar Rock faces the risk of strong competition from larger, more established companies that have greater financial resources and established market presence.
- The regulatory landscape and the approval process for new drugs can be lengthy and challenging. Scholar Rock may encounter difficulties in obtaining regulatory clearance for its therapies, leading to delays or market access limitations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.